Why join us?

Parabilis Medicines is a highly distinctive young biopharmaceutical company whose intention is to grow over time into the ranks of major therapeutics companies. Our foundational platform of Helicon™ therapeutics are peptides capable of efficient cell entry and modulation of both protein-protein and protein-DNA interactions. Through Helicon therapeutics, Parabilis is poised to revolutionize the medical possibilities for patients by precisely drugging intracellular targets long understood to be significant drivers of disease but never before drugged due to the limitations of existing drug modalities to act within the cell.

An important distinctive element of Parabilis is our lead program FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor. This compound is approximately 18 months and ~50 patients into our early development program for patients with advanced solid tumors, most importantly colorectal cancer. There are few products in the ecosystem with the medical and economic potential of FOG-001. Parabilis is fully leveraging the unprecedented potential Helicons present by deploying proprietary, custom-built machine learning and computational methods as part of its discovery and development process. Parabilis Medicines has raised more than $500 million to date from leading life sciences investors. Parabilis Medicines is headquartered in Cambridge, Mass.

What’s the opportunity?

Parabilis is seeking a highly skilled and motivated biochemist/cell biologist with drug discovery experience to join our DeNovo Discovery team. The successful candidate will guide the development and execution of assays to address critical questions pertaining to cellular uptake and endosomal escape of our therapeutic compounds. This will involve working closely with a cross-functional team of chemists, biologists, and data scientists to design and perform experiments that assess Helicon™ uptake efficiency, cytosolic exposure (CE), and endosomal escape mechanisms.

This person will also support ongoing efforts to identify potential next-generation molecules by performing routine testing to measure cytosolic exposure and cellular uptake.

Key objectives include:

• Identify core assays to measure and optimize CE of native Helicons™ and refine our existing CE-related assays to better align with project needs
• Outline key non-CE measurements that are important for contextualizing CE data and incorporate these assays accordingly
• Inform drug design and our understanding of Helicon™ structure-activity relationships through data-driven insights
• Design cell-based functional assays to quantify compound internalization and subcellular localization using techniques such as cell fractionation, mass spectrometry and confocal microscopy.

What you’ll need to be successful:

• Ph.D. in cell and molecular biology, biochemistry, pharmacology or related field with 3+ years of academic or industry experience. Master's degree with 8+ years of industry experience in drug discovery setting.
• Experience with liquid chromatography-mass spectrometry is strongly preferred
• Demonstrated experience in developing cell-based uptake assays and proximity-dependent activity assays, including but not limited to NanoBiT and NanoBRET, is a plus.
• Experience with biophysical/biochemical assay development such as ITC, DSF, MST, FP, TR-FRET, and structural biology, etc. a plus.
• Experience in oncology and peptide drug discovery strongly preferred
• Self-motivation, ability to work independently, excellent organization skills that enable multitasking and working within timelines is required
• Ability to adapt and exercise flexibility for changing platform needs, workflows, and projects
• Strong interpersonal and communication skills are essential

• Able to work on-site and attend in-person meetings

Core Values

Parabilis Medicines is a team of passionate pioneers who are trailblazing the future of precision medicine with the aim of making a meaningful difference in the lives of patients. The company is committed to promoting an inspiring and flourishing working environment for all employees across the business, in all departments, and driving innovation for patient benefit.

• Growth-Minded. We’re inventing a new class of medicines—one applicable to therapeutic targets that have been dreamt about, but always considered impossible to drug. Our work requires us to be curious, humble and adaptable.
• In(ter)dependent. We are fiercely independent as a leader in defying the limitations of current therapeutic modalities, and interdependent as a team as we work collaboratively to shift drug discovery paradigms and provide patients with better treatment options.
• Patient-focused. We are deeply focused on patient outcomes, and all energy in the company is focused on science as it translates to patient impact.
• All-In. We’re All-In on solving some of the hardest scientific challenges and delivering one of the most effective new classes of drugs in history.

As an equal opportunity employer, Parabilis Medicines values diversity and welcomes applicants of all backgrounds and experiences. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.

30 Acorn Park Drive | Cambridge, MA 02140 | www.parabilismed.com